Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15935284 | 0.74 | ELANE (0.38) | ELANEKDM4EPOLBRAB9ALMNA | |
| SCHEMBL14866999 | 0.70 | LMNA (0.32) | ELANELMNAPIK3CG | |
| SCHEMBL10173407 | 0.69 | ELANE (0.37) | ELANEKDM4EPOLBRAB9ALMNA | |
| SCHEMBL17088001 | 0.69 | ELANE (0.37) | ELANEKDM4EPOLBRAB9ALMNA | |
| SCHEMBL10173403 | 0.68 | ELANE (0.42) | ELANEKDM4EPOLBLMNA | |
| SCHEMBL14788337 | 0.67 | ELANE (0.38) | ELANEKDM4EPOLBRAB9ALMNA | |
| SCHEMBL12309182 | 0.67 | ELANE (0.49) | ELANEKDM4EPOLBRAB9A | |
| SCHEMBL13587135 | 0.66 | LMNA (0.43) | ELANEKDM4EPOLBRAB9ALMNA | |
| SCHEMBL13080778 | 0.64 | ELANE (0.42) | ELANEKDM4EPOLBLMNA | |
| SCHEMBL13138493 | 0.64 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130096136-A1 | Inhibitors of Protein Tyrosine Kinase Activity | METHYLGENE INC. (CA) | 2013-04-18 | — | — | US | disclosed |
| US-7626030-B2 | Compounds and methods of use | AMGEN INC. (US) | 2009-12-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130096136-A1 | Inhibitors of Protein Tyrosine Kinase Activity | KDR, FLT1, FLT4 | ELANE 2950/4885KDM4E 3367/4885POLB 2854/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.